

PTO/SB/08B (07-05) Approved for use through 07/31/2006, OMB 0851-0331 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete If Known Substitute for form 1449/PTO **Application Number** 10/517,319 INFORMATION DISCLOSURE **Filing Date** July 15, 2005 STATEMENT BY APPLICANT First Named Inventor Philippe A. TESSIER Art Unit 1644 (Use as many sheets as necessary) Examiner Name Sharon Marsha M. TSAY Wen **Attorney Docket Number** Sheet 6013-149US of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/S.W./		DONATO, Rosario: "Functional roles of S100 proteins, calclum-binding proteins of the EF-hand type" Biochimica et Biophysica Acta 1450 (1999), pages 191-231	
/S.W./		RAVASI, Timothy et al.: "Probing the S100 protein family through genomic and functional analysis" Genomics 84 (2004), pages 10-22	
		·	
		·	
		·	

Examiner '	Date	\neg
Signature /Sharon Wen/	Considered 08/15/2007	

*EXAMINER: Initial if reference considered, whether or not distion is in conformance with MPEP 609. Draw line through cliation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (opdonat). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.89. The Information is required to obtain or retain a benefit by the public which is to fife (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete this form ant/or suggestions for reducing this burdon, should be sant to the Chief information Officer, U.S. Petent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (09-06)
Approved for use through 03/31/2007, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete If Known		
			Application Number	10/517,319	
INFORMAT	TON DIS	CLOSURE	Filing Date	July 15, 2005	
STATEMENT BY APPLICANT			First Named Inventor	Philippe A. TESSIER	
/Itsa as m	(Use as many sheets as necessary)			1650. 1644	
1000 ms many offers as necessary,			Examiner Name	Marsha M. TSAY Sharon Wen	
Sheet 1	of	1	Attorney Docket Number	6013-149US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/S.W./		Mauro PERRETTI et al., Mobilizing Lipocortin 1 in adherent human leukocytes downregulates their transmigration, Nat Medicine, 1996, 2: 1259-1262	

Examiner	/Sharon Wen/	Date	00/45/0007
Signature	/Snaron vven/	Considered	08/15/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial in reference considered, whether of not citation is an conformance with MPEP 809. Draw are through citation a not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid CMP

		ct of 1995, no persons a	Complete if Known			
Substitute for form 1449/PTO		Application Number	10/517,319	- V		
INFORMA	TION DIS	CLOSURE	Filing Date	July 15, 2005		
STATEMENT BY APPLICANT			First Named Inventor	Philippe A. TESSII	ER	
			Art Unit	1056	1644	
(Use as many sheets as necessary)			Examiner Name	TSAY, Marcha M	Sharon Wen	
Sheet 1	of	1	Attorney Docket Number	6013-149US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Υ²
/S.W./		EUE et al., Transendothelial migration of 27E10+ human monocytes, International Immunology, 2000, Vol. 12: 1593-1604	
/S.W./		HARRISON et al., Oxidation Regulates the Inflammatory Properties of the Murine S100 Protein S100A8, The Journal of Biological Chemistry, 1999, Vol.274: 8561-8569	
/S.W./		NEWTON et al., The Human S100 Protein MRP-14 Is a Novel Activator of the β2 Integrin Mac-1 on Neutrophils, The Journal of Immunology, 1998, 160: 1427-1435	
		·	
•			
		·	

Examiner	/Sharon Wen/	T I	Datc	08/15/2007
Signature	/Sharon Wen/	į (Considered	00/13/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drew line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whather or not olation is in conformance with MPEP 909. Draw late introduction of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, prepering, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Commission of the Patents of the Chief Information Officer, U.S. Patent and Information Information Officer, Information Officer, Information Officer, Information Officer, Information I Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A/B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ollection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to resp

Substitute for form 1449A and B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known					
Application Number	10/517,319				
Filing Date	07/15/2005				
First Named Inventor	Philippe Tessier				
Art Unit	1653				
Examiner Name					
Attorney Docket Number	6013-149US MG/pd				

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pagas, Columns, Unes Where Relevant Passages or Relevant Figures Appear		
		US 5,731,166	03/24/1998	Geczy Carolyn et al.			
		US 6,103,497	08/15/2000	Corley Neil et al.			
				·			
					· · · · · · · · · · · · · · · · · · ·		
					1		
					,		
		1111 1111 1111 1111 1111					
			1				
				,			
			·				
		·					
		 					
			1	•			
			1				
			1				
	 -			<u> </u>			
		 	1				
			 				
			 				

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code3 - Number4 - Kind Code5'(# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant Of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T,
		EP 0,263,072	04/06/1988	Ciba Geigy Ag		Ė
						\perp
						\vdash
						二
	ļ ,					╁
						\perp
					I	

1TO/SB/08A/B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known Substitute for form 1449A and B/PTO Application Number 10/517,319 INFORMATION DISCLOSURE 07/15/2005 Filing Date First Named Inventor Philippe Tessier STATEMENT BY APPLICANT Art Unit (use as many sheets as necessary) Sharon **Examiner Name** 6013-149US MG/pd of Attorney Docket Number leet

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when eppropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published kamin T2 er nitials DUNN C J ET AL: "Increased expression of neutrophil MRP8 and MRP14 is associated with vascular /S.W./ adhesion molecule activation and differential leukocyte infiltration in delayed-type hypersensitivity suggesting a proinflammatory role for \$100 calcium-binding proteins" Biosis, XP002242712 abstract YEN TINA ET AL: *Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli", Blood, W.B. Saunders, Philadelphia, VA, US, vol. 90, no. 12, 15 December 1997, pages 4812-4821 LAGASSE E ET AL: "Mouse MRP8 and MRP14, two Intracellular calcium-binding proteins associated with the development of the myeloid lineage" Blood, W.B. Saunders, Philadelphia, VA, US, vol. 79, 1992, pages LACKMANN M.: "Identification of a chemotactic domain of the pro-inflammatory S100 Protein CP-10", Journal of immunology, The Williams and Wilkins Co. Baltimore, US, vol. 150, no 7, April 1, 1993, pages 2981-2991 DEVERY JANNINE M ET AL: "Acute inflammatory activity of the S100 protein CP-10: Activation of neutrophils in vivo and in vitro." Journal of immunology, vol. 152, no. 4, 1994, pages 1888-1897 RYCKMAN CARLE ET AL: "Proinflammatory activities of \$100: Proteins \$100A8, \$100A9, and \$100A8/A9 induce neutrophil chemotaxis and adhesion." Journal of immunology, vol. 170, no. 6, 15 March 2003, pages 3233-3242 ROULEAU PASCAL ET AL: "The calcium-binding protein \$100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis., Clinical Immunology (Orlando), vol. 107, no.1, 20 April 2003, pages 46-54

Examiner Signature	/Sharon Wen/	Date Considered	08/15/2007

^{*}EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.